James M Cleary

James M Cleary

UNVERIFIED PROFILE

Are you James M Cleary?   Register this Author

Register author
James M Cleary

James M Cleary

Publications by authors named "James M Cleary"

Are you James M Cleary?   Register this Author

33Publications

1306Reads

35Profile Views

Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.

Lancet Gastroenterol Hepatol 2019 Sep 9;4(9):711-720. Epub 2019 Jul 9.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2468-1253(19)30189-XDOI Listing
September 2019

Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.

Cancer Discov 2018 02 3;8(2):196-215. Epub 2017 Nov 3.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-17-0833DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809290PMC
February 2018

A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone.

Invest New Drugs 2017 04 23;35(2):189-197. Epub 2017 Jan 23.

University of Pittsburgh Cancer Institute/UPMC, 5150 Centre Avenue, Fifth Floor, Pittsburgh, PA, 15232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-016-0409-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352756PMC
April 2017

A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan.

Invest New Drugs 2017 02 16;35(1):68-78. Epub 2016 Nov 16.

University of California - San Francisco, Box 1705, UCSF, San Francisco, CA, 94143-1705, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-016-0399-7DOI Listing
February 2017

Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer.

BMC Cancer 2016 07 13;16:468. Epub 2016 Jul 13.

Center for Esophageal and Gastric Cancer, Dana-Farber Brigham and Women's Cancer Center and Gastrointestinal Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://bmccancer.biomedcentral.com/articles/10.1186/s12885-0
Publisher Site
http://dx.doi.org/10.1186/s12885-016-2485-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944495PMC
July 2016

Update on the role of imaging in management of metastatic colorectal cancer.

Radiographics 2014 Nov-Dec;34(7):1908-28

From the Departments of Imaging (S.H.T., K.W.K., M.N., S.A.H., K.M.K., J.P.J., N.H.R., A.B.S.) and Medical Oncology (J.M.C.), Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA 02215; and Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (S.H.T., K.W.K., M.N., S.A.H., K.M.K., J.P.J., N.H.R., A.B.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/rg.347130090DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4386871PMC
November 2015

A phase 1 study of ABT-806 in subjects with advanced solid tumors.

Invest New Drugs 2015 Jun 17;33(3):671-8. Epub 2015 Apr 17.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-015-0234-6DOI Listing
June 2015

Randomized trial of TAS-102 for refractory metastatic colorectal cancer.

N Engl J Med 2015 May;372(20):1909-19

From the Dana-Farber Cancer Institute, Boston (R.J.M, J.M.C.); University Hospitals, Leuven and KU Leuven, Leuven (E.V.C., H.P.), and Universitaire Ziekenhuizen Antwerp, Edegem (M.P.) - all in Belgium; University of Pisa, Pisa (A.F.), IRCCS Azienda Ospedaliera Universitaria San Martino-Istituto Nazionale per la Ricerca Sul Cancro, Genoa (A.S.), and the Fondazione Poliambulanza Istituto Ospedaliero, Brescia (A.Z.) - all in Italy; National Cancer Center Hospital East, Chiba (T.Y., A.O.), Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo (N.M.), Shizuoka Cancer Center, Shizuoka (K.Y.), National Cancer Center Hospital, Tokyo (Y.S.), Hokkaido University Hospital, Hokkaido (Y.K.), and Taiho Pharmaceutical, Tokyo (M.I.) - all in Japan; Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla, Seville (R.G.-C.), and Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona (J.T.) - all in Spain; Centre Eugène Marquis, Rennes, France (E.B.); Royal Melbourne Hospital, Melbourne, VIC, Australia (B.T.); University of Southern California Norris Comprehensive Cancer Center, Los Angeles (H.-J.L.); Yale Cancer Center, New Haven, CT (H.H.); Taiho Oncology, Princeton, NJ (F.B., H.M.); and Stathmi, New Hope, PA (L.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1414325DOI Listing
May 2015

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.

Cancer Discov 2014 May 13;4(5):546-53. Epub 2014 Mar 13.

Departments of 1Medical Oncology and 2Biostatistics and Computational Biology, 3Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; Departments of 4Medicine and 5Pathology, Brigham and Women's Hospital, Harvard Medical School; 6Division of Hematology/Oncology, Massachusetts General Hospital, Boston; 7Broad Institute of Harvard and MIT; 8Department of Biology, Whitehead Institute for Biomedical Research; 9Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts; and 10Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0353DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122326PMC
May 2014

Crizotinib as salvage and maintenance with allogeneic stem cell transplantation for refractory anaplastic large cell lymphoma.

J Natl Compr Canc Netw 2014 Mar;12(3):323-6; quiz 326

From aDana-Farber Cancer Institute, Harvard Medical School and bBrigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; cUniversity of Rochester Medical Center, University of Rochester, Rochester, New York; and dMassachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2014.0034DOI Listing
March 2014

Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.

J Clin Oncol 2014 Jan 9;32(2):68-75. Epub 2013 Dec 9.

Leena Gandhi, Sara M. Tolaney, James M. Cleary, and Geoffrey I. Shapiro, Dana-Farber Cancer Institute; Eunice L. Kwak, Massachusetts General Hospital; Shuchi S. Pandya, Beth Israel Deaconess Medical Center, Boston; Anna Berkenblit and Mizue Krygowski, Aveo Pharmaceuticals; Revathi Ananthakrishnan and Kathleen W. Turnbull, Inventiv Health, Cambridge, MA; Rastislav Bahleda, Antoine Hollebecque, and Jean-Charles Soria, Insitut Gussav Roussy, Villejuif, France; Richat Abbas and Yali Liang, Pfizer, Collegeville, PA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2012.47.2787
Publisher Site
http://dx.doi.org/10.1200/JCO.2012.47.2787DOI Listing
January 2014

Sunitinib rechallenge in metastatic renal cell carcinoma patients.

Cancer 2010 Dec 2;116(23):5400-6. Epub 2010 Nov 2.

Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.25583
Publisher Site
http://dx.doi.org/10.1002/cncr.25583DOI Listing
December 2010

Development of phosphoinositide-3 kinase pathway inhibitors for advanced cancer.

Curr Oncol Rep 2010 Mar;12(2):87-94

Department of Medical Oncology, Early Drug Development Center, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA, 02115, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s11912-010-0091
Web Search
http://link.springer.com/10.1007/s11912-010-0091-6
Publisher Site
http://dx.doi.org/10.1007/s11912-010-0091-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3883721PMC
March 2010

Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver.

Oncologist 2009 Nov 30;14(11):1095-105. Epub 2009 Oct 30.

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2009-0152DOI Listing
November 2009